"10.1371_journal.pone.0093283","plos one","2014-03-28T00:00:00Z","Airie Kim; Seth Rivera; Dana Shprung; Donald Limbrick; Victoria Gabayan; Elizabeta Nemeth; Tomas Ganz","Department of Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, United States of America; Department of Pathology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, United States of America","Conceived and designed the experiments: AK SR EN TG. Performed the experiments: AK DS DL VG. Analyzed the data: AK SR DS DL EN TG. Wrote the paper: AK EN TG.","T.G. and E.N. are cofounders, shareholders and officers of Intrinsic LifeSciences, a company developing hepcidin diagnostics. E.N. and T.G. hold patents related to the therapeutic use of hepcidin and its regulators. Please see below for the patents' details, including names and numbers: 1) Competitive Regulation of Hepcidin mRNA by Soluble and Cell-Associated Hemojuvelin (Ganz, Lin, Goldberg) US Patent no. 7,534,764, date of issuance May 19, 2009 2) Mini-Hepcidin Peptides and Methods of Using thereof (Ganz, Nemeth, Preza, Ruchala) US Patent no. 8,435,941, date of issuance May 7, 2013 3) PENDING: Erythroferrone and ERFE Polypeptides and Methods of Regulating Iron Metabolism (Ganz, Nemeth) PCT Patent Application No. PCT/US2013/67771. This does not alter the authors' adherence to PLOS ONE policies on sharing data and materials.","2014","03","Airie Kim","AK",7,TRUE,4,4,6,3,TRUE,TRUE,FALSE,0,NA,FALSE
